Your browser doesn't support javascript.
loading
Application of the adverse outcome pathway framework to genotoxic modes of action.
Sasaki, Jennifer C; Allemang, Ashley; Bryce, Steven M; Custer, Laura; Dearfield, Kerry L; Dietz, Yasmin; Elhajouji, Azeddine; Escobar, Patricia A; Fornace, Albert J; Froetschl, Roland; Galloway, Sheila; Hemmann, Ulrike; Hendriks, Giel; Li, Heng-Hong; Luijten, Mirjam; Ouedraogo, Gladys; Peel, Lauren; Pfuhler, Stefan; Roberts, Daniel J; Thybaud, Véronique; van Benthem, Jan; Yauk, Carole L; Schuler, Maik.
Affiliation
  • Sasaki JC; Genentech, Inc., South San Francisco, California.
  • Allemang A; Procter & Gamble, Mason, Ohio.
  • Bryce SM; Litron Laboratories, Rochester, New York.
  • Custer L; Bristol-Myers Squibb Company, Drug Safety Evaluation, New Brunswick, New Jersey.
  • Dearfield KL; Burke, Virginia.
  • Dietz Y; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Elhajouji A; Novartis Pharma AG, Basel, Switzerland.
  • Escobar PA; Merck &Co. Inc., West Point, Pennsylvania.
  • Fornace AJ; Georgetown University, Washington, District of Columbia.
  • Froetschl R; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
  • Galloway S; Merck &Co. Inc., West Point, Pennsylvania.
  • Hemmann U; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Hendriks G; Toxys, Leiden, The Netherlands.
  • Li HH; Georgetown University, Washington, District of Columbia.
  • Luijten M; National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Ouedraogo G; L'oréal Recherche & Innovation, Aulnay-Sous-Bois, France.
  • Peel L; Health and Environmental Sciences Institute, Washington, District of Columbia.
  • Pfuhler S; Procter & Gamble, Mason, Ohio.
  • Roberts DJ; Charles River Laboratoires, Skokie, Illinois.
  • Thybaud V; Sanofi, Research and Development, Preclinical Safety, Vitry-sur-Seine, France.
  • van Benthem J; National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Yauk CL; Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada.
  • Schuler M; Pfizer Inc, World Wide Research and Development, Groton, Connecticut.
Environ Mol Mutagen ; 61(1): 114-134, 2020 01.
Article in En | MEDLINE | ID: mdl-31603995
ABSTRACT
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61114-134, 2020. © 2019 Wiley Periodicals, Inc.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adverse Outcome Pathways / Mutagenicity Tests / Mutagens Limits: Animals / Humans Language: En Journal: Environ Mol Mutagen Journal subject: BIOLOGIA MOLECULAR / SAUDE AMBIENTAL Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adverse Outcome Pathways / Mutagenicity Tests / Mutagens Limits: Animals / Humans Language: En Journal: Environ Mol Mutagen Journal subject: BIOLOGIA MOLECULAR / SAUDE AMBIENTAL Year: 2020 Document type: Article